Cardiovascular diseases are a major cause
of death across the globe. According to the World Health Organization,
the number of deaths caused by these diseases is expected to surpass 23
million by 2030. These are largely lifestyle diseases and about 16% of
deaths caused in 2012 were attributed to high blood pressure. Various
classes of drugs used to treat cardiac disorders include calcium channel
blockers, anti-adrenergic agents, anti-arrhythmic agents, diuretic
agents, and angiotensin-converting enzyme (ACE) inhibitors.
Nephrological and urological disorders are common complications of
cardiovascular diseases and diabetes. Diuretic agents are often
prescribed drug class for treating cardiovascular diseases as well as
nephrological and urological disorders. Diuretics alternatively termed
as water pills aid in elimination of water and salts from the body.
Diuretics are primarily used to treat edema caused by renal dysfunction
such as nephrotic syndrome, acute glomerulonephritis, and chronic renal
failure. Diuretics stimulate kidneys to eliminate water and salts from
the body, which helps reduce swelling.
Benicar HCT (olmesartan and
hydrochlorothiazide) by Daiichi Sankyo and Exforge HCT (amlodipine,
hydrochlorothiazide, and valsartan) by Novartis have lost their patents
in 2016 and 2014, respectively. Diovan HCT (valsartan and
hydrochlorothiazide) by Novartis was among the top selling drugs in the
cardiovascular segment, which generated total sales of US$ 3,524 Mn in
2013. Hyzaar by Merck and Micardis by Boehringer Ingelheim
Pharmaceuticals, Inc. are other key drugs available in the market.
Increase in cardiovascular diseases, rise in the number of hypertensive
patients, escalation in renal and kidney disorders, changing life styles
of people, unhealthy habits, and increasing life expectancy of people
are key drivers propelling the global diuretics drugs market. However,
certain side effects associated with diuretic drugs restrict their use.
The global diuretic agents market was valued at US$ 724.6 Mn in 2013 and
is anticipated to increase during the forecast period.
The global diuretic agents market can be
segmented based on type, application, distribution channel, and region.
In terms of type, the global diuretic agents market can be classified
into osmotic diuretics such as mannitol; carbonic anhydrase inhibitors
such as acetazolamide (dichlorphenamide, metazolamide); loop diuretics
such as bumetanide, furosemide, ethacrynic acid, torasemide; thiazides
& thiazide-like diuretics such as (chlorothiazide), clopamide,
hydrochlorothiazide, chlorthalidone, indapamide; Na+ channel antagonists
such as triamterene, amiloride; and aldosterone antagonists such as
spironolactone and eplerenone. Based on application, the global diuretic
agents market can be segmented into hypertension, edema,
hypercalciuria, diabetes insipidus, and others. In terms of distribution
channel, the global diuretics agents market can be segmented into
hospital pharmacies, clinics, hospitals, retail pharmacies, and online
pharmacies.
Geographically, the global diuretics
agents market can be segmented into five major regions: North America,
Europe, Asia Pacific (APAC), Latin America, and Middle East &
Africa. Asia Pacific held a leading share of the market, followed by
North America, in 2016. These two regions are expected to retain their
market position from 2017 to 2025. Rising prevalence of hypertensive
complications and increasing government initiatives that appear to be
moving toward shorter period of patent exclusivity for new drug
applications are some factors driving the market in these regions.
Moreover, large population, increasing disposable income, and growing
awareness among patients are a few factors propelling the market in Asia
Pacific. Europe and the Middle East & Africa are likely to create
significant growth opportunities for the diuretics agents market during
the forecast period. This is attributed to growing geriatric population
in these regions.
Key players operating in the global
diuretics agents market include Merck & Co., Inc., Boehringer
Ingelheim GmbH, Novartis AG, and Teva Pharmaceuticals Industries Ltd.
No comments:
Post a Comment